Taconic Biosciences News

Rensselaer, NY — April 15, 2019 - Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces the launch of TruBIOME™, a first of its kind solution enabling the generation and maintenance of mice with custom microbiome profiles. TruBIOME™ was developed to meet the research community's need for a microbiome solution that affords increased predictability, reproducibility, and systems biology insight within mouse model use....  Read More

In a recent article published in Genetic Engineering News, the CRISPR technology is highlighted as a tool for clinical gene therapy in humans. In February of this year, the first patient was dosed with a CRISPR-Cas9 therapeutic in a Phase I/II trial for treatment of β-thalassemia (a type of inherited blood disorder). However, before CRISPR can become a broad-spectrum treatment for all genetic disorders, tests in animal...  Read More

Rensselaer, NY — April 1, 2019 - Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces it has obtained a license to the Wild Mouse gut microbiome from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). Investigators at the NIDDK studied wild mice gut microbiota, finding it differs dramatically from that of...  Read More

A recent article published in LaboratoryEquipment.com features Taconic Biosciences's Product Manager Jennifer Phelan and the topic of lab animal health standards. "Fifty years ago, the chief concern about a lab animal's health was the presence of infectious disease," writes Phelan. She continues to state that current concerns for lab animal health are instead focused on defining health standards for barriers and keeping these standards consistent across all...  Read More

An article published this month in Seeker.com highlights the most recent Rodent Research space mission which launched to the International Space Station on December 5th, 2018 carrying 40 BALB/cAnNTac mice from Taconic Biosciences. The study had three specific aims: To evaluate muscle atrophy under microgravity conditions To quantify changes in tissue-specific molecular markers and To characterize the effects of microgravity on bone density during and after the...  Read More

Boston, MA - February 7, 2019 - H.I.G. Capital ("H.I.G."), a leading global private equity investment firm with $30 billion of equity capital under management, is pleased to announce that one of its affiliates has partnered with the management team of Taconic Biosciences, Inc., ("Taconic" or the "Company") to support the Company's growth as a leading global provider of research models and services to the pharmaceutical, biotechnology,...  Read More

Rensselaer, NY — January 31, 2019 - Taconic Biosciences' Board of Directors has selected Nancy J. Sandy to succeed Dr. Robert J. Rosenthal as Chief Executive Officer (CEO). Effective January 14, Ms. Sandy took the company's top leadership position. Dr. Rosenthal, who held the position for four and a half years, continues his association with Taconic, leading external growth initiatives as Chief Innovation Officer and holds positions...  Read More

At the 2019 Taconic Biosciences Global Sales Meeting, employees compiled and donated 85+ activity bags to the Cystic Fibrosis Department at Boston Children's Hospital. The colorful, fun goodies were provided to the nursing staff at the hospital who then shared with the patients. Taconic has participated in a great deal of Cystic Fibrosis related research and is honored to have the opportunity to further contribute to those...  Read More

Rensselaer, NY — January 17, 2019 - Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces the completion of a recent mission to the International Space Station. This project represents a collaboration between the International Space Station (ISS) National Lab, National Aeronautics and Space Administration (NASA), Bioserve Space Technologies with support from the Leidos Corporation, and Taconic. Taconic has participated in several spaceflight...  Read More

An article published early this year in Drug Discovery News highlights the evolving role of gut microbiome in the progression of autoimmune diseases, neurodegeneration, and host responses to various treatments. Specifically, Taconic Biosciences's Dr. Alex Maue is interviewed as stating that there is "so much interplay between not only the gut, but other systems", as a key feature of how this field is growing. The focus of...  Read More